

# Tupras (TUPRS TI)

# Buy: Another set of strong results in Q4 2015

- Q4 2015 EBITDA beat consensus by 24%, marking a strong end to 2015 when EBITDA jumped TRY3.0bn to TRY3.8bn
- We estimate 18% EBITDA growth in 2016e from a strong base; we expect strong dividend payments starting this year
- Maintain Buy rating with unchanged target price of TRY90

**Strong performance continues:** Tupras posted stronger-than-expected Q4 2015 results with EBITDA ahead of both consensus and our forecasts. As such, FY2015 was the best ever year for Tupras with a record EBITDA of TRY3,784m and net income of TRY2,550m. Tupras' management expects the strong performance to continue in 2016, which is in line with our forecast outlined in *Upgrade to Buy: Heading for peak performance in 2016*, 29 January 2016. We expect 2016 to benefit from: (i) full-year operation of residuum upgrade project (RUP), (ii) balanced refined products' supply-demand dynamics and overall supportive refining sector environment, (iii) inventory gains if there is a crude price rise over the year (HSBC expects Brent to rise to USD55/b by Q4 2016), and (iv) increased imports of favourably priced Iranian crude by Tupras.

**Q4 2015 EBITDA was ahead of expectations:** Tupras' Q4 2015 EBITDA of TRY1,189m was 24% and 12% ahead of Research Turkey consensus and our estimates, respectively. The beat vs our forecast is explained by lower cost of sales (-5% vs HSBCe) which is likely driven by lower crude procurement costs, lower opex (-3% vs HSBCe) and lower crude oil inventory losses (USD43m vs our estimate of USD50m loss). The refinery capacity utilisation rate (CUR) stood at 112% (+5ppt vs our forecast), which compares with 82% in Q4 2014 and was helped by full-scale operation of RUP. This also resulted in a 9ppt y-o-y rise in middle distillate yields to 52%. However, the Q4 2015 net income of TRY815m was 4% and 23% lower than consensus and our forecast, respectively, which was largely driven by TRY344m FX-related losses.

**Maintain Buy with TP unchanged at TRY90.0:** Tupras' management expects Turkey's diesel consumption growth to remain strong in 2016 (after 16% y-o-y growth in 11M 2015). The company could also possibly increase Iranian crude imports during the year as it is available at a favourable discount to Brent. For FY2016e, management guided for a CUR of 100% (vs our forecast of 98%), Med-Urals complex gross refining margins of USD3.5-4.0/b (vs our USD4.0/b) and Tupras' net refining margin of USD5.8-6.3/b (vs our USD5.4/b estimate). However, we maintain our estimates. We think the announcement related to dividend payments with respect to the 2015 results could be a near-term trigger for Tupras' share price performance. Tupras' management said during the Q4 2015 results conference call that the dividend payments will be strong and the company will pay out the maximum amount possible from FY2015 statutory profits. We forecast DPS of TRY6.0 for 2015 vs. IBES consensus estimate of TRY3.75.

Turkey

EQUITIES OIL & GAS

	AIN BU	Y	
TARGET PRICE (TRY)		REVIOUS TARGET	(TRY)
SHARE PRICE (TRY) 72.05 (as of 15 Feb 2016)		-24.9%	
MARKET DATA	40.040	Free float	4000/
Market cap (TRYm) Market cap (USDm)	18,043 6,112	BBG	100% TUPRS TI
3m ADTV (USDm)	35.7	RIC	TUPRS.IS
		-	

FINANCIALS AND RATIOS (TRY)					
12/2015a	12/2016e	12/2017e	12/2018e		
10.18	10.42	9.88	9.12		
11.18	-	-			
-8.9	-	-			
8.39	8.89	8.70	8.04		
7.1	6.9	7.3	7.9		
8.3	8.7	8.2	7.6		
6.4	5.8	6.1	5.8		
35.3	29.5	25.1	21.3		
	12/2015a 10.18 11.18 -8.9 8.39 7.1 8.3 6.4	12/2015a 12/2016e   10.18 10.42   11.18 -   -8.9 -   8.39 8.89   7.1 6.9   8.3 8.7   6.4 5.8	12/2015a 12/2016e 12/2017e   10.18 10.42 9.88   11.18 - -   -8.9 - -   8.39 8.89 8.70   7.1 6.9 7.3   8.3 8.7 8.2   6.4 5.8 6.1		

#### 52-WEEK PRICE (TRY)



Source: Thomson Reuters IBES, HSBC estimates

#### Bulent Yurdagul\*

Head CEEMEA Consumers Research & Co-Head Turkish Equity Research HSBC Yatirim Menkul Degerler A.S. bulentyurdagul@hsbc.com.tr 90 212 376 46 12

#### Govinder Kumar\*

Associate, Bangalore

\* Employed by a non-US affiliate of HSBC Securities (USA) Inc, and is not registered/ qualified pursuant to FINRA regulations

## **Disclaimer & Disclosures**

This report must be read with the disclosures and the analyst certifications in the Disclosure appendix, and with the Disclaimer, which forms part of it.

**Issuer of report:** HSBC Yatirim Menkul Degerler A.S.

View HSBC Global Research at: https://www.research.hsbc.com

# Financials & valuation

#### **Financial statements**

Veerte	12/2015a	12/2016-	12/2017-	12/2018e
Year to Profit & loss summary (TRYm		12/2016e	12/2017e	12/20186
Revenue	36,893	35,489	45,260	56,575
EBITDA	,	,		
	3,784	3,950	3,605	3,625
Depreciation & amortisation	-486	-525	-522	-522
Operating profit/EBIT	3,298	3,425	3,083	3,103
Net interest	-349	-166	-95	-274
PBT	2,225	3,278	3,110	2,869
HSBC PBT	2,225	3,278	3,110	2,869
Taxation	339	-656	-622	-574
Net profit	2,550	2,609	2,475	2,284
HSBC net profit	2,550	2,609	2,475	2,284
Cash flow summary (TRYm)				
Cash flow from operations	-155	3,665	3,246	2,994
Capex	-961	-800	-650	-600
Cash flow from investment	-959	-800	-650	-600
Dividends	6	-1,503	-1,566	-1,485
Change in net debt	3,035	-1,362	-1,031	-909
FCF equity	-1,043	2,519	2,163	2,067
Balance sheet summary (TRY	m)			
Intangible fixed assets	59	59	59	59
Tangible fixed assets	15,970	15,917	15,734	15,525
Current assets	8,675	6,254	8,595	10,993
Cash & others	3,028	835	1,865	2,773
Total assets	25,470	22,997	25,155	27,344
Operating liabilities	6.988	6,951	8,187	9,566
Gross debt	9,919	6,364	6,363	6,363
Net debt	6,892	5,530	4,499	3,590
Shareholders' funds	8,305	9,412	10,321	11,120
Invested capital	14,688	14,445	14,337	14,238
inteotou oupitui	14,000	17,770	14,007	14,200

### Ratio, growth and per share analysis

Year to	12/2015a	12/2016e	12/2017e	12/2018e
Y-o-y % change				
Revenue	-7.1	-3.8	27.5	25.0
EBITDA	379.5	4.4	-8.7	0.6
Operating profit	521.1	3.9	-10.0	0.7
PBT	1111.7	47.3	-5.1	-7.7
HSBC EPS	74.8	2.3	-5.1	-7.7
Ratios (%)				
Revenue/IC (x)	3.0	2.4	3.1	4.0
ROIC	31.4	18.8	17.1	17.4
ROE	35.3	29.5	25.1	21.3
ROA	13.4	11.9	11.5	9.9
EBITDA margin	10.3	11.1	8.0	6.4
Operating profit margin	8.9	9.7	6.8	5.5
EBITDA/net interest (x)	10.8	23.8	37.8	13.3
Net debt/equity	82.4	58.3	43.2	32.0
Net debt/EBITDA (x)	1.8	1.4	1.2	1.0
CF from operations/net debt		66.3	72.2	83.4
Per share data (TRY)				
EPS reported (diluted)	10.18	10.42	9.88	9.12
HSBC EPS (diluted)	10.18	10.42	9.88	9.12
DPS	6.00	6.25	5.93	5.47
Book value	33.16	37.58	41.22	44.41

### Key forecast drivers

	12/2017e	12/2018e
4.0	3.5	3.5
5.6	5.3	5.3
2.1	2.5	2.5
2.95	3.00	3.00
	5.6 2.1	5.6 5.3   2.1 2.5


HSBC (

# Valuation data

Year to	12/2015a	12/2016e	12/2017e	12/2018e
EV/sales	0.7	0.6	0.5	0.4
EV/EBITDA	6.4	5.8	6.1	5.8
EV/IC	1.6	1.6	1.5	1.5
PE*	7.1	6.9	7.3	7.9
PB	2.2	1.9	1.7	1.6
FCF yield (%)	-6.0	14.5	12.5	11.9
Dividend yield (%)	8.3	8.7	8.2	7.6
* Based on HSBC EPS (dilute	(he			

\* Based on HSBC EPS (diluted)

#### Price relative



Note: Priced at close of 15 Feb 2016




#### Tupras financial forecast revisions (TRYm)

		2016e			_2017e	
	New	Old	Change	New	Old	Change
Sales	35,489	35,491	0%	45,260	45,260	0%
EBITDA	3,950	3,950	0%	3,605	3,605	0%
Net income	2,609	2,609	0%	2,475	2,475	0%
Source: HSBC estimates						

#### Tupras' capacity utilisation rate was above 100% for the last three quarters of 2015



Monthly Med-Urals gross refining margins (USD/b)



Source: Tupras

Source: Thomson Reuters Datastream

#### Valuation and risks

#### Valuation

We have updated our model for the Q4 2015 actual results. We value Tupras using a DCF (50% weight) and multiples-based approaches (25% weight each to PE and EV/EBITDA).

Our DCF valuation for Tupras is TRY94.5 per share (from TRY85.5, due to lower WACC). This is derived using a benchmark Med-Urals refining margin of USD4.0/bbl for 2016 and USD3.5/b thereafter, a risk-free-rate assumption of 9.5%, an equity risk premium of 5.5%, and a beta of 0.91, resulting in a CoE of 14.5%. We use cost of debt of 5.0%, leading to a WACC of 11.1% (from 11.7% due to higher debt at the end of 2015). Our DCF model also assumes a terminal growth rate of 3%.

Our EV/EBITDA valuation method yields a valuation of TRY75.8 (from TRY83.6) per share based on the one-year forward sector average multiple of 5.0x (from 5.5x) and our EBITDA estimate for 2016e.

We arrive at a PE-based valuation of TRY95.1 (from TRY103.8) per share using the one-year forward multiple of 7.0x (from 8.6x) and our 2016e net income estimate. On relative valuation multiples, we think Tupras should trade in line with its peer average on forward-looking multiples.

The weighted average of these three valuation methods, rounded to the nearest whole number, results in a fair value target price of TRY90 (unchanged). Our target price implies upside of 24.9%; we therefore maintain our Buy rating on Tupras.

#### Risks

The downside risks to our estimates and rating include lower-than-expected refining margins and fuel demand in the company's key market Turkey, fiscal and regulatory related risks.



# **Disclosure appendix**

#### **Analyst Certification**

The following analyst(s), economist(s), and/or strategist(s) who is(are) primarily responsible for this report, certifies(y) that the opinion(s) on the subject security(ies) or issuer(s) and/or any other views or forecasts expressed herein accurately reflect their personal view(s) and that no part of their compensation was, is or will be directly or indirectly related to the specific recommendation(s) or views contained in this research report: Bulent Yurdagul

#### Important disclosures

#### Equities: Stock ratings and basis for financial analysis

HSBC believes an investor's decision to buy or sell a stock should depend on individual circumstances such as the investor's existing holdings, risk tolerance and other considerations and that investors utilise various disciplines and investment horizons when making investment decisions. Ratings should not be used or relied on in isolation as investment advice. Different securities firms use a variety of ratings terms as well as different rating systems to describe their recommendations and therefore investors should carefully read the definitions of the ratings used in each research report. Further, investors should carefully read the entire research report and not infer its contents from the rating because research reports contain more complete information concerning the analysts' views and the basis for the rating.

#### From 23rd March 2015 HSBC has assigned ratings on the following basis:

The target price is based on the analyst's assessment of the stock's actual current value, although we expect it to take six to 12 months for the market price to reflect this. When the target price is more than 20% above the current share price, the stock will be classified as a Buy; when it is between 5% and 20% above the current share price, the stock may be classified as a Buy or a Hold; when it is between 5% below and 5% above the current share price, the stock will be classified as a Hold; when it is between 5% and 20% above the current share price, the stock will be classified as a Hold; when it is between 5% and 20% below the current share price, the stock may be classified as a Hold; when it is between 5% and 20% below the current share price, the stock may be classified as a Hold or a Reduce; and when it is more than 20% below the current share price, the stock will be classified as a Reduce.

Our ratings are re-calibrated against these bands at the time of any 'material change' (initiation or resumption of coverage, change in target price or estimates).

Upside/Downside is the percentage difference between the target price and the share price.

#### Prior to this date, HSBC's rating structure was applied on the following basis:

For each stock we set a required rate of return calculated from the cost of equity for that stock's domestic or, as appropriate, regional market established by our strategy team. The target price for a stock represented the value the analyst expected the stock to reach over our performance horizon. The performance horizon was 12 months. For a stock to be classified as Overweight, the potential return, which equals the percentage difference between the current share price and the target price, including the forecast dividend yield when indicated, had to exceed the required return by at least 5 percentage points over the succeeding 12 months (or 10 percentage points for a stock classified as Volatile\*). For a stock to be classified as Underweight, the stock was expected to underperform its required return by at least 5 percentage points over the succeeding 12 months (or 10 percentage points for a stock classified as Volatile\*). For a stock to be classified as Underweight, the stock was expected to underperform its required return by at least 5 percentage points over the succeeding 12 months (or 10 percentage points for a stock classified as Volatile\*). For a stock to be classified as Underweight, the stock was expected to underperform its required return by at least 5 percentage points over the succeeding 12 months (or 10 percentage points). Stocks between these bands were classified as Neutral.


\*A stock was classified as volatile if its historical volatility had exceeded 40%, if the stock had been listed for less than 12 months (unless it was in an industry or sector where volatility is low) or if the analyst expected significant volatility. However, stocks which we did not consider volatile may in fact also have behaved in such a way. Historical volatility was defined as the past month's average of the daily 365-day moving average volatilities. In order to avoid misleadingly frequent changes in rating, however, volatility had to move 2.5 percentage points past the 40% benchmark in either direction for a stock's status to change.



As of 16 February 2016, the dis	stributior	n of all ratings published is as follows:
Buy	48%	(28% of these provided with Investment Banking Services)
Hold	38%	(27% of these provided with Investment Banking Services)
Sell	14%	(17% of these provided with Investment Banking Services)

For the purposes of the distribution above the following mapping structure is used during the transition from the previous to current rating models: under our previous model, Overweight = Buy, Neutral = Hold and Underweight = Sell; under our current model Buy = Buy, Hold = Hold and Reduce = Sell. For rating definitions under both models, please see "Stock ratings and basis for financial analysis" above.

### Share price and rating changes for long-term investment opportunities



Rating & target price history						
From	То	Date				
Overweight	Neutral	15 May 2013				
Neutral	Hold	06 April 2015				
Hold	Buy	29 January 2016				
Target price	Value	Date				
Price 1	57.00	15 May 2013				
Price 2	51.00	04 November 2013				
Price 3	46.00	27 January 2014				
Price 4	51.00	02 May 2014				
Price 5	54.00	23 May 2014				
Price 6	61.00	23 January 2015				
Price 7	59.20	06 April 2015				
Price 8	68.50	24 June 2015				
Price 9	77.20	03 September 2015				
Price 10	81.70	09 November 2015				
Price 11	90.00	29 January 2016				
Source: HSBC						

### **HSBC & Analyst disclosures**

None of the below disclosures applies to any of the stocks featured in this report.

- 1 HSBC has managed or co-managed a public offering of securities for this company within the past 12 months.
- 2 HSBC expects to receive or intends to seek compensation for investment banking services from this company in the next 3 months.
- 3 At the time of publication of this report, HSBC Securities (USA) Inc. is a Market Maker in securities issued by this company.
- 4 As of 31 January 2016 HSBC beneficially owned 1% or more of a class of common equity securities of this company.
- 5 As of 31 December 2015, this company was a client of HSBC or had during the preceding 12 month period been a client of and/or paid compensation to HSBC in respect of investment banking services.
- 6 As of 31 December 2015, this company was a client of HSBC or had during the preceding 12 month period been a client of and/or paid compensation to HSBC in respect of non-investment banking securities-related services.
- 7 As of 31 December 2015, this company was a client of HSBC or had during the preceding 12 month period been a client of and/or paid compensation to HSBC in respect of non-securities services.
- 8 A covering analyst/s has received compensation from this company in the past 12 months.
- 9 A covering analyst/s or a member of his/her household has a financial interest in the securities of this company, as detailed below.
- A covering analyst/s or a member of his/her household is an officer, director or supervisory board member of this 10 company, as detailed below.
- 11 At the time of publication of this report, HSBC is a non-US Market Maker in securities issued by this company and/or in securities in respect of this company



HSBC and its affiliates will from time to time sell to and buy from customers the securities/instruments, both equity and debt (including derivatives) of companies covered in HSBC Research on a principal or agency basis.

Analysts, economists, and strategists are paid in part by reference to the profitability of HSBC which includes investment banking, sales & trading, and principal trading revenues.

Whether, or in what time frame, an update of this analysis will be published is not determined in advance.

Economic sanctions imposed by the EU and OFAC prohibit transacting or dealing in new debt or equity of Russian SSI entities. This report does not constitute advice in relation to any securities issued by Russian SSI entities on or after July 16 2014 and as such, this report should not be construed as an inducement to transact in any sanctioned securities.

For disclosures in respect of any company mentioned in this report, please see the most recently published report on that company available at www.hsbcnet.com/research.

#### Additional disclosures

- 1 This report is dated as at 17 February 2016.
- 2 All market data included in this report are dated as at close 15 February 2016, unless otherwise indicated in the report.
- 3 HSBC has procedures in place to identify and manage any potential conflicts of interest that arise in connection with its Research business. HSBC's analysts and its other staff who are involved in the preparation and dissemination of Research operate and have a management reporting line independent of HSBC's Investment Banking business. Information Barrier procedures are in place between the Investment Banking, Principal Trading, and Research businesses to ensure that any confidential and/or price sensitive information is handled in an appropriate manner.



# Disclaimer

#### Legal entities as at 30 May 2014

'UAE' HSBC Bank Middle East Limited, Dubai; 'HK' The Hongkong and Shanghai Banking Corporation Limited, Hong Kong; 'TW' HSBC Securities (Taiwan) Corporation Limited; 'CA' HSBC Bank Canada, Toronto; HSBC Bank, Paris Branch; HSBC France; 'DE' HSBC Trinkaus & Burkhardt AG, Düsseldorf; 000 HSBC Bank (RR), Moscow; 'IN' HSBC Securities and Capital Markets (India) Private Limited, Mumbai; 'JP' HSBC Securities (Japan) Limited, Tokyo; 'EG' HSBC Securities Egypt SAE, Cairo; 'CN' HSBC Investment Bank Asia Limited, Beijing Representative Office; The Hongkong and Shanghai Banking Corporation Limited, Singapore Branch; The Hongkong and Shanghai Banking Corporation Limited, Securities (Vertiles Branch; The Hongkong and Shanghai Banking Corporation Limited, Securities (Vertiles Branch; HSBC Securities (London, Madrid, Milan, Stockholm, Tel Aviv; 'US' HSBC Securities (USA) Inc, New York; HSBC Yatirim Menkul Degerler AS, Istanbul; HSBC México, SA, Institución de Banca Múltiple, Grupo Financiero HSBC; HSBC Bank Brasil SA – Banco Múltiplo; HSBC Bank Australia Limited; HSBC Bank Argentina SA; HSBC Saudi Arabia Limited; The Hongkong and Shanghai Banking Corporation Limited, New Zealand Branch incorporated in Hong Kong SAR; The Hongkong and Shanghai Banking Corporation Limited, Bangkok Branch

Issuer of report

HSBC Yatirim Menkul Degerler A.S. Buyukdere Caddesi No: 122 / D Kat:9 Esentepe/Sisli 34394 Istanbul, Turkey Telephone: +90 212 376 46 00 Fax: +90 212 376 49 13 www.research.hsbc.com www.hsbcyatirim.com.tr

This document has been issued by HSBC Yatrım Menkul Degerler A.S. (HSBC) for the information of its customers only. If it is received by a customer of an affiliate of HSBC, its provision to the recipient is subject to the terms of business in place between the recipient and such affiliate.

HSBC has based this document on information obtained from sources it believes to be reliable but which it has not independently verified; HSBC makes no guarantee, representation or warranty and accepts no responsibility or liability as to its accuracy or completeness. Expressions of opinion are those of the Research Department of HSBC only and are subject to change without notice.

The information, comments and recommendations involved here are not within the scope of investment consultancy. Investment consultancy services are only provided within the framework of the investment consultancy agreement as agreed between brokerage companies, portfolio management companies, banks not accepting deposits, and the customer. The conclusions arrived at here are based upon the preferred calculation method and/or the personal opinions of the individuals responsible for the comments and recommendations, so they may not be appropriate for your financial situation and risk and return preferences. Therefore, any investment decision made only on the basis of the information involved here may not lead to the optimum results.

HSBC and its affiliates and/or their officers, directors and employees may have positions in any securities mentioned in this document (or in any related investment) and may from time to time add to or dispose of any such securities (or investment). HSBC and its affiliates may have assumed an underwriting commitment in the securities of companies discussed in this document (or in related investments), may sell them to or buy them from customers on a principal basis and may also perform or seek to perform investment banking or underwriting services for or relating to those companies and may also be represented in the supervisory board or any other committee of those companies.

The information and opinions contained within the research reports are based upon rates of taxation applicable at the time of publication but which are subject to change from time to time. Past performance is not necessarily a guide to future performance. The value of any investment or income may go down as well as up and you may not get back the full amount invested. Where an investment is denominated in a currency other than the local currency of the recipient of the research report, changes in the exchange rates may have an adverse effect on the value, price or income of that investment. In case of investments for which there is no recognised market it may be difficult for investors to sell their investments or to obtain reliable information about its value or the extent of the risk to which it is exposed.

HSBC Securities (USA) Inc. accepts responsibility for the content of this research report prepared by its non-US foreign affiliate. All U.S. persons receiving and/or accessing this report and wishing to effect transactions in any security discussed herein should do so with HSBC Securities (USA) Inc. in the United States and not with its non-US foreign affiliate, the issuer of this report.

In the UK this report may only be distributed to persons of a kind described in Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005. The protections afforded by the UK regulatory regime are available only to those dealing with a representative of HSBC Bank plc in the UK. In Singapore, this publication is distributed by The Hongkong and Shanghai Banking Corporation Limited, Singapore Branch for the general information of institutional investors or other persons specified in Sections 274 and 304 of the Securities and Futures Act (Chapter 289) ("SFA") and accredited investors and other persons in accordance with the conditions specified in Sections 275 and 305 of the SFA. This publication is not a prospectua se defined in the SFA. It may not be further distributed in whole or in part for any purpose. The Hongkong and Shanghai Banking Corporation Limited Singapore Branch is regulated by the Monetary Authority of Singapore. Recipients in Singapore should contact a "Hongkong and Shanghai Banking Corporation Limited, Singapore Branch is repeated of any matters arising from, or in connection with this report. In Canada, this publication may be distributed by HSBC Securities (Canada) Inc for the information of its customers only. All inquiries by such recipients must be directed to HSBC Securities (Canada) Inc. In Australia, this publication may be distributed by HSBC Stockbroking (Australia) Pty Limited. In Malaysia, this publication may be distributed by HSBC Securities (Canada) Inc for the Hongkong and Shanghai Banking Corporation Limited, Secul Securities Branch ("HBAP SLS") or The Hongkong and Shanghai Banking Corporation Limited, Secul Securities Branch ("HBAP SLS") or The Hongkong and Shanghai Banking Corporation Limited, Secul Securities Interestor as defined interestores and Capital Markets Act ("FSCMA"). This publication is not a prospectus as defined in the FSCMA. It may not be further distributed in whole or in part for any purpose. Both HBAP SLS and HBAP SLS and HBA

In Australia, this publication has been distributed by The Hongkong and Shanghai Banking Corporation Limited (ABN 65 117 925 970, AFSL 301737) for the general information of its "wholesale" customers (as defined in the Corporations Act 2001). Where distributed to retail customers, this research is distributed by HSBC Bank Australia Limited (AFSL No. 232595). These respective entities make no representations that the products or services mentioned in this document are available to persons in Australia or are necessarily suitable for any particular person or appropriate in accordance with local law. No consideration has been given to the particular investment objectives, financial situation or particular needs of any recipient. In Canada, this document has been distributed by HSBC Bank Canada and/or its affiliates. Where this document contains market updates/overviews, or similar materials (collectively deemed "Commentary" in Canada although other affiliate jurisdictions may term "Commentary" as either "macro-research" or "research"), the Commentary is not an offer to sell or a solicitation of an offer to sell or subscribe for, any financial product or instrument (including, without limitation, any currencies, securities, commodities or other financial instruments).

This communication is only intended for investment professionals within Article 19 of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005. Persons who do not have professional experience in matters relating to investments should not rely on it. HSBC Yatırım Menkul Degerler A.S. is regulated and authorised by the Central Bank of Turkey, Capital Markets Board, Ministry of Finance, Takasbank and is a member of Istanbul Stock Exchange, Takasbank (Turkish Custodian Bank) and the Association of Capital Market Intermediary Institutions of Turkey.

© Copyright 2016, HSBC Yatirim Menkul Degerler A.S., ALL RIGHTS RESERVED. No part of this publication may be reproduced, stored in a retrieval system, or transmitted, on any form or by any means, electronic, mechanical, photocopying, recording, or otherwise, without the prior written permission of HSBC. MICA (P) 073/06/2015 and MICA (P) 021/01/2016